NFKB1 and allergic disease: Desloratadine has been reported to antagonize the increase of MDA, the final product of lipid peroxidation, and to reduce endogenous antioxidant glutathione (GSH) in the allergy model [8]. Roumestan et al. showed that there was a desloratadine inhibited NF-κB production whereas [9] Wu et al. argued that desloratadine inhibited both basal and histamine-induced NF-κB [10].